Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2014 10:02 ET | Source: Zealand Pharma A/S

Zealand to present at upcoming Credit Suisse 2014 London Healthcare Conference

Copenhagen, 2014-02-20 16:02 CET (GLOBE NEWSWIRE) -- Investor News No. 1/2014 Zealand to present at upcoming Credit Suisse 2014 London Healthcare...
February 20, 2014 10:02 ET | Source: Zealand Pharma A/S

Zealand præsenterer på kommende Credit Suisse 2014 London Healthcare-konference

København, 2014-02-20 16:02 CET (GLOBE NEWSWIRE) -- Investornyheder No. 1/2014 Zealand præsenterer på kommende Credit Suisse 2014 London...
February 06, 2014 02:46 ET | Source: Zealand Pharma A/S

Zealand meddeler, at Sanofi har offentliggjort starten på LixiLan fase III-udviklingsprogrammet for”fixed-ratio”-kombinationen af Lantus® og Lyxumia®

København, 2014-02-06 08:46 CET (GLOBE NEWSWIRE) -- Selskabsmeddelelse Nr. 3/2014 Zealand meddeler, at Sanofi har offentliggjort starten på LixiLan fase...
February 06, 2014 02:46 ET | Source: Zealand Pharma A/S

Zealand informs that Sanofi has announced initiation of the LixiLan Phase III clinical program for the Fixed-Ratio combination of Lantus® and Lyxumia®

Copenhagen, 2014-02-06 08:46 CET (GLOBE NEWSWIRE) -- Company Announcement No. 3/2014 Zealand informs that Sanofi has announced initiation of the LixiLan Phase...
January 20, 2014 01:31 ET | Source: Zealand Pharma A/S

Zealand og Boehringer Ingelheim ændrer deres udviklingsprogram for nye dobbeltvirkende glukagon/GLP-1-agonister til behandling af type 2-diabetes og/eller fedme til en ny lead-kandidat, som vil erstatte ZP2929

København, 2014-01-20 07:31 CET (GLOBE NEWSWIRE) -- Selskabsmeddelelse Nr. 2/2014 Zealand og Boehringer Ingelheim ændrer deres udviklingsprogram for nye dobbeltvirkende...
January 20, 2014 01:31 ET | Source: Zealand Pharma A/S

Zealand and Boehringer Ingelheim to change development program on novel dual-acting glucagon/GLP-1 receptor agonists to treat Type 2 diabetes and/or obesity with a new lead compound that will replace ZP2929

Copenhagen, 2014-01-20 07:31 CET (GLOBE NEWSWIRE) -- Company Announcement No. 2/2014 Zealand and Boehringer Ingelheim to change development program on novel dual-acting glucagon/GLP-1 receptor...
January 15, 2014 18:00 ET | Source: Zealand Pharma A/S

CORRECTION: Zealand announces advance by Sanofi of LixiLan, the single injection Lyxumia®/Lantus® combination product, towards Phase III development and a related milestone payment

Copenhagen, 2014-01-16 00:00 CET (GLOBE NEWSWIRE) -- Company Announcement No. 1/2014 ─ The first LixiLan Phase III study protocol has now been approved, triggering a USD 15 million...
January 15, 2014 18:00 ET | Source: Zealand Pharma A/S

Korrektion: Zealand meddeler, at Sanofi tager Lyxumia®/Lantus®-kombinationsproduktet, LixiLan til enkelt injektion videre imod fase III-udvikling, og at selskabet modtager relateret milepælsbetaling

København, 2014-01-16 00:00 CET (GLOBE NEWSWIRE) -- Selskabsmeddelelse Nr. 1/2014 Korrektion: Dette er en korrektion af meddelelse nr. 1/2014 udsendt af Zealand Pharma onsdag den 15. januar kl....
January 15, 2014 11:04 ET | Source: Zealand Pharma A/S

Zealand meddeler, at Sanofi tager Lyxumia®/Lantus®-kombinationsproduktet, LixiLan til enkelt injektion videre imod fase III-udvikling, og at selskabet modtager relateret milepælsbetaling

København, 2014-01-15 17:04 CET (GLOBE NEWSWIRE) -- Selskabsmeddelelse Nr. 1/2014 ─ Den første LixiLan fase III-studieprotokol er nu godkendt, hvilket udløser en betaling på 82...
January 15, 2014 11:04 ET | Source: Zealand Pharma A/S

Zealand announces advance by Sanofi of LixiLan, the single injection Lyxumia®/Lantus® combination product, towards Phase III development and a related milestone payment

Copenhagen, 2014-01-15 17:04 CET (GLOBE NEWSWIRE) -- Company Announcement No. 1/2014 ─ The first LixiLan Phase III study protocol has now been approved, triggering a USD 15 million...